In addition to agonistic monoclonal antibodies, the small molecular drug imatinib, an inhibitor of T-regs and IDO pathway in tumor cells [84, 85], was combined with photodynamic/thermal therapy for photoimmunotherapy in a preclinical model of melanoma [86]. This evidence concerns the gene IDO1 and neoplasm.